Oxford University and AstraZeneca Plc and the other from China's CanSino Biologics - induced immune responses in healthy volunteers without causing dangerous side effects, according to studies published on Monday in The Lancet.A third different type of vaccine from Pfizer Inc and German biotech BioNTech also showed promise in a small, early study released on Monday, adding to hopes that at least one will prove safe and effective.The following are five takeaways from Monday's developments, drawn in part from an editorial in The Lancet medical journal:1.
The Oxford/AstraZeneca and CanSino teams released results from early trials of COVID-19 vaccines that use harmless versions of another virus, or viral vector, to deliver genetic material from.